Association between insulin monotherapy versus insulin plus metformin and the risk of all-cause mortality and other serious outcomes: A retrospective cohort study

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Holden, Sarah E ^a,b   Jenkins Jones, Sara ^b   Currie, Craig J ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Global Epidemiology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HAZARD RATIO; HEART DISEASE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; COMBINATION DRUG THERAPY; MIDDLE AGED; RISK FACTOR;

AGED; CAUSE OF DEATH; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84968809053     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153594     Document Type: Article

References (31)

1. Holden SE, Gale EAM, Jenkins-Jones S, Currie CJ. How many people inject insulin? UK estimates from 1991 to 2010. Diabetes Obes Metab. 2014; 16: 533-9.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-79. doi: 10.2337/dc12-0413 PMID: 22517736
3. Goudswaard AN, Furlong NJ, Valk GD, Stolk RP, Rutten GEHM. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2004: CD003418. PMID: 15495054
4. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002; 137: 25-33. PMID: 12093242
5. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Methylglyoxal Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. 1999; 4: 198-202.
6. Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJM, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009; 169: 616-25. doi: 10.1001/archinternmed.2009.20 PMID: 19307526
7. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52: 1766-77. doi: 10.1007/s00125-009-1440-6 PMID: 19572116
8. Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab. 2010; 21: 610-8. doi: 10.1016/j.tem.2010.06.007 PMID: 20663687
9. Wheeler S, Moore K, Forsberg CW, Riley K, Floyd JS, Smith NL, et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia. 2013; 56: 1934-43. doi: 10.1007/s00125-013-2958-1 PMID: 23797633
10. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010; 3: 1451-61.
11. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 2012; 17: 813-22. doi: 10.1634/theoncologist.2011-0462 PMID: 22643536
12. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013; 62: 922-34. doi: 10.1016/j.metabol.2013.01.014 PMID: 23419783
13. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013; 8: e71583. doi: 10.1371/journal.pone.0071583 PMID: 23936520
14. Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia. 2012; 55: 2593-603. doi: 10.1007/s00125-012-2653-7 PMID: 22875195
15. Holden SE, Jenkins-Jones S, Morgan CL, Schernthaner G, Currie CJ. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose-response association with all-cause mortality, cardiovascular events and incident cancer. Diabetes Obes Metab. 2015; 17: 350-62. doi: 10.1111/dom.12412 PMID: 25399739
16. Gamble J-M, Simpson SH, Eurich DT, Majumdar SR, Johnson JA. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab. 2010; 12:.47-53. doi: 10.1111/j. 1463-1326.2009.01125.x PMID: 19788429
17. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014; 311: 2288-96. doi: 10.1001/jama.2014.4312 PMID: 24915260
18. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CLl. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013; 98: 668-77. doi: 10.1210/jc.2012-3042 PMID: 23372169
19. Clinical Practice Research Datalink (CPRD). Clinical Practice Research Datalink. 2016. Available: http://www.cprd.com/intro.asp
20. Charlson M, Pompei P, Ales K, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-83. PMID: 3558716
21. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jørgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010; 53: 2546-53. doi: 10.1007/s00125-010-1906-6 PMID: 20838985
22. Hemmingsen B, Lundby L, Wetterslev J. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ. 2012; 344: e1771. doi: 10.1136/bmj.e1771 PMID: 22517929
23. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-65. PMID: 9742977
24. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, et al; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010; 170: 1892-9. doi: 10.1001/archinternmed.2010.409 PMID: 21098347
25. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose- lowering therapies in people with type 2 diabetes. J Clin Endocrin Metab. 2012; 97: 1-8.
26. van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia. 2012; 55: 654-65. doi: 10.1007/s00125-011-2390-3 PMID: 22127412
27. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New Engl J Med. 2012; 367: 319-28. doi: 10.1056/NEJMoa1203858 PMID: 22686416
28. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29: 254-8. PMID: 16443869
29. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Brit J Gen Pr. 2010; 60: e128-36.
30. Joint Formulary Committee. British National Formulary (online). BMJ Group and Pharmaceutical Press. Available: http://www.medicinescomplete.com.
31. Harrell F, Lee K, Mark D. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361-87. PMID: 8668867